Fight Alzheimer’s By Taking Part In A Clinical Trial

Share Button

Courtesy of PRWeb and Harvard Health Publications…..please leave your comments below…..

seniorwoman2Several clinical trials are testing promising new drugs to prevent and treat dementia.

Women fear developing Alzheimer’s disease more than having a heart attack or stroke or developing cancer. One reason is that cancer, heart attack, and stroke are treatable, but there is little an individual can do to arrest the progress of Alzheimer’s disease. One thing individuals can do is to take part in a clinical trial, reports the July 2015 Harvard Women’s Health Watch.

“There are now opportunities to do something, perhaps to reduce your own risk and also to help the next generation see Alzheimer’s disease as completely preventable,” says Dr. Reisa Sperling, professor of neurology at Harvard Medical School.

Clinical trials to prevent the onset of Alzheimer’s disease and to slow its progress are now under way across the country and around the world.

Preventing Alzheimer’s disease:

New or upcoming clinical trials are testing drugs that go after amyloid plaques. These are clumps of protein that form in the brain. Plaque deposits have been linked to the development of Alzheimer’s disease. Large nationwide studies of plaque-fighting drugs in people who have amyloid plaques in their brains but no symptoms of Alzheimer’s include the following:

The A4 study. Dr. Sperling is a principal investigator of this study, which is testing the effectiveness of solanezumab, an antibody that helps remove amyloid from the brain.

The LEARN study. Researchers will use imaging and memory tests to compare people without amyloid plaques to the placebo group in the A4 study. The goal is to look for other factors that may contribute to cognitive decline or cognitive resilience.

The A5 study. Researchers will test the effects of an oral drug called a beta-secretase inhibitor, which is designed to prevent new amyloid plaques from developing in the brain.

Treating Alzheimer’s disease:

Two major trials will test drugs designed to treat people who have mild or moderate Alzheimer’s disease. The Amaranth Study will test the effectiveness of a drug called a beta-secretase inhibitor. Another study called NOBLE will test different doses of the drug T-817MA, which protects brain cells against the toxic effects of amyloid.

Read the full-length article: “There is something you can do about Alzheimer’s disease—join a study”

Also in the July 2015 Harvard Women’s Health Watch:

* When is an urgent-care clinic as good as the ER?

* Avoiding ankle injuries

* Why statins aren’t for everyone

Harvard Women’s Health Watch is available from Harvard Health Publications, the publishing division of Harvard Medical School, for $20 per year. Subscribe at http://www.health.harvard.edu/newsletters/womens or by calling 877-649-9457 (toll-free). Contact us for a complimentary copy of the newsletter, or to receive our press releases directly.

Iowa Researcher Awarded 2015 ACSM-AMSSM Clinical Research Grant

Share Button

This article is courtesy of ACSM, please share your comments below…..

didyouknow?M. Kyle Smoot, MD, is the 2015 recipient of the ACSM Foundation-AMSSM Foundation Clinical Research Grant for his research titled, “The relationship between muscle damage and acute kidney injury biomarkers in American football players during preseason workouts.”

The latest in a series of collaborative projects between the American College of Sports Medicine and the American Medical Society for Sports Medicine, the joint Clinical Research Grant Committee selects a single proposal to receive a $20,000 award. This is the 3rd year of the partnership for the annual joint clinical research grant awards. “The grant review committee is pleased to award funding for Dr. Smoot’s research proposal that will investigate new serum markers of acute kidney injury in athletes,” said Suzanne Hecht, M.D., who chaired the joint organization review committee. “This research has the potential to play a role in the management of the athlete with suspected rhadomyolysis along with other possible applications.”

Dr. Smoot is a clinical assistant professor at the University of Iowa Carver College of Medicine, where he also serves as the Program Director for its sports medicine fellowship program. He has conducted research on adequacy of pre-participation cardiovascular screening in NCAA collegiate athletes, concussion protocol for student athletes and assessment of muscle damage in asymptomatic football players during strenuous activity. He received his medical degree from Wright State University School of Medicine in Dayton, OH, residency at the University of Kentucky Medical Center and completed a primary care sports medicine fellowship at UK.

The primary purpose of the ACSMF-AMSSMF Clinical Research Grant Award is to foster original scientific investigations with a strong clinical focus among physician members of ACSM and AMSSM. A secondary intent of the grant program is to foster the development of the principal investigator’s research education by requiring that a portion of the funds to be applied to meet this goal. The review committee sought research proposals that investigate research questions within the broad discipline of sports medicine. The criteria required proposals to be led by physicians who are members of both ACSM and AMSSM.